نتایج جستجو برای: dolutegravir

تعداد نتایج: 953  

Journal: :Open Forum Infectious Diseases 2022

Abstract Background Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV) infected people worldwide. Patients with HIV who have latent TB are 20-30 times more likely to develop active TB. Integrated antiretroviral therapy (ART) early treatment for tuberculosis recommended due improved morbidity and mortality, however, there can be serious drug interactions. Rifam...

Journal: :Global health, science and practice 2015
James D Shelton

EFV clearly reduces effectiveness of implants. However, the reduced effectiveness still appears better compared with short-acting methods overall, at least for the initial period of implant use, and may be acceptable to many women. We need better data on effectiveness, especially over the long term and on whether ENG implants (Implanon) might be more effective than LNG implants (Jadelle). Commu...

Journal: :The Journal of Infectious Diseases 2018

2017
Lucia Taramasso Elena Ricci Barbara Menzaghi Giancarlo Orofino Simone Passerini Giordano Madeddu Canio Vito Martinelli Giuseppe Vittorio De Socio Nicola Squillace Stefano Rusconi Paolo Bonfanti Antonio Di Biagio T Quirino P Bonfanti E Ricci C Bellacosa P Maggi L Calza C Abeli B Menzaghi B M Celesia C Grosso A Stagno F Vichi F Mazzotta C Martinelli G Penco G Cassola A Di Biagio L Taramasso L A Nicolini C Dentone C Molteni L Palvarini A Scalzini L Carenzi G Rizzardini L Valsecchi L Cordier S Rusconi V Colombo M Galli M Franzetti G V De Socio E Mazzotta G Parruti G Madeddu P Bagella M S. Mura R Libertone A Antinori S Di Giambenedetto G Orofino M Guastavigna P Caramell

Weight gain and body mass index (BMI) increase are central issues in patients living with HIV who need to minimize the risk of metabolic disease. Information collected through the SCOLTA cohort revealed significant 1-year BMI increase in patients treated with dolutegravir (P = .004), raltegravir (P = .0004), elvitegravir (P = .004), darunavir (P = .0006), and rilpivirine (P = .029). BMI gain co...

2015
Mark A. Wainberg Ying-Shan Han

Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More interestingly, clinical resistance mutations to DTG in treatment-naive patents have not been observed to this date. This review su...

Journal: :Canadian journal of microbiology 2016
Mark A Wainberg Ying-Shan Han Thibault Mesplède

Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development o...

Journal: :The Journal of Infectious Diseases 2018

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید